Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NCT01438775
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
192
Enrollment
INDUSTRY
Sponsor class
Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG:
NX-1207
Sponsor
Nymox Corporation